ORYZON Genomics
Calle Sant Ferran 74
Cornella de Llobregat
Barcelona
08940
Tel: 34-93-5151313
Fax: 34-93-3774028
Website: http://www.oryzon.com/
Email: info@oryzon.com
155 articles about ORYZON Genomics
-
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
4/8/2024
Oryzon Genomics, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune checkpoint inhibitors in first line small cell lung cancer.
-
ORYZON to Provide Corporate Progress Updates at Several Events in April 2024
4/5/2024
Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in April.
-
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
2/5/2024
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in February and March.
-
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
1/19/2024
Oryzon Genomics, S.A. today announced that it will host a virtual KOL event on Thursday, January 25, 2024 at 10:00 am ET to briefly review, then discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disorder (BPD).
-
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
1/5/2024
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced topline results from the Phase IIb PORTICO trial, evaluating the efficacy and safety of vafidemstat in Borderline Personality Disorder (BPD).
-
ORYZON to Provide Corporate Progress Updates at Several Events in January
1/3/2024
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in January.
-
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
12/4/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration with the ALS Association.
-
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
11/21/2023
Oryzon Genomics, S.A. announced the entry into a new convertible bonds financing agreement with Nice & Green in bonds convertible into new shares for a total amount of €45 Million.
-
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
11/7/2023
Oryzon Genomics, S.A. announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder.
-
ORYZON to Provide Corporate Progress Updates at Several Events in November
11/6/2023
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in November.
-
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
10/27/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update on recent developments.
-
ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
10/10/2023
Oryzon Genomics, S.A. announced today that the company presented an update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the 36th European College held on October 7-10 in Barcelona, Spain.
-
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
10/3/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today the granting, through a provisional resolution proposal, of two aids within the Spanish research plan 2021-2023 for public-private collaboration projects: the DICTIONIS Project with a budget of 951,000 euros (€) and the MODERN Project with a budget of €1,328,594.
-
ORYZON to Provide Corporate Progress Updates at Several Events in October
10/2/2023
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in October.
-
ORYZON to Give Updates on Corporate Progress in September
9/5/2023
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in September.
-
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
7/26/2023
Oryzon Genomics, S.A. today reports that full patient recruitment has been completed in its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder.
-
ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023
7/24/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the half-year ended June 30, 2023 and provided a corporate update on recent developments.
-
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
7/5/2023
Oryzon Genomics, S.A. today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BPD).
-
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
6/27/2023
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced the voting results from its Annual General Meeting of Shareholders held on Monday, June 26, 2023, in Madrid.
-
Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
6/21/2023
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) presented yesterday positive preclinical efficacy data of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, in an oral communication at the 2023 Peripheral Nerve Society annual meeting (PNS-2023) held in Copenhagen from 17-20 June 2023.